RK-682

CAT:
804-HY-135564A
Size:
200 µg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
RK-682 - image 1

RK-682

  • Description:

    RK-682 is the inhibitor for protein tyrosine phosphatase (PTPase), heparanase, phospholipase A2 and HIV-1 protease. RK-682 inhibits the dephosphorylation of CD45 (IC50 is 54 μM) and VHR (IC50 is 2.0 μM), and thereby inhibits the ERK signaling pathway. RK-682 inhibits the cell viability of cancer cell MGH-U3, T24 and UROtsa with IC50s of 78.2, 43.2 and 145 nM, respectively, arrests the cell cycle at G1/S phase, inhibits the cell migration and autophagy in MGH-U3 and T24[1][2][3].
  • UNSPSC:

    12352005
  • Target:

    Autophagy; ERK; HIV Protease; Phosphatase; Phospholipase
  • Type:

    Reference compound
  • Related Pathways:

    Anti-infection; Autophagy; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Stem Cell/Wnt
  • Applications:

    COVID-19-anti-virus
  • Field of Research:

    Cancer; Infection
  • Assay Protocol:

    https://www.medchemexpress.com/rk-682.html
  • Purity:

    99.0
  • Smiles:

    CCCCCCCCCCCCCCCC(C1=C([C@@H](CO)OC1=O)O)=O
  • Molecular Formula:

    C21H36O5
  • Molecular Weight:

    368.51
  • References & Citations:

    [1]Usui T, et al., Design and synthesis of a dimeric derivative of RK-682 with increased inhibitory activity against VHR, a dual-specificity ERK phosphatase: implications for the molecular mechanism of the inhibition. Chem Biol. 2001 Dec;8 (12) :1209-20.|[2]Hamaguchi T, et al., RK-682, a potent inhibitor of tyrosine phosphatase, arrested the mammalian cell cycle progression at G1phase. FEBS Lett. 1995 Sep 18;372 (1) :54-8. |[3]Tatsumi Y, et al., Inhibition of Heparanase Expression Results in Suppression of Invasion, Migration and Adhesion Abilities of Bladder Cancer Cells. Int J Mol Sci. 2020 May 27;21 (11) :3789.
  • Shipping Conditions:

    Blue Ice
  • Storage Conditions:

    -20°C (Powder, sealed storage, away from moisture)
  • Scientific Category:

    Reference compound1
  • Clinical Information:

    No Development Reported
  • CAS Number:

    [150627-37-5]